These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Melatonin as a proteasome inhibitor. Is there any clinical evidence? Vriend J; Reiter RJ Life Sci; 2014 Oct; 115(1-2):8-14. PubMed ID: 25219883 [TBL] [Abstract][Full Text] [Related]
46. Antitumor activity of bortezomib alone and in combination with TRAIL in human acute myeloid leukemia. Conticello C; Adamo L; Vicari L; Giuffrida R; Iannolo G; Anastasi G; Caruso L; Moschetti G; Cupri A; Palumbo GA; Gulisano M; De Maria R; Giustolisi R; Di Raimondo F Acta Haematol; 2008; 120(1):19-30. PubMed ID: 18716397 [TBL] [Abstract][Full Text] [Related]
47. Synergistic induction of apoptosis in breast cancer cells by cotreatment with butyrate and TNF-alpha, TRAIL, or anti-Fas agonist antibody involves enhancement of death receptors' signaling and requires P21(waf1). Chopin V; Slomianny C; Hondermarck H; Le Bourhis X Exp Cell Res; 2004 Aug; 298(2):560-73. PubMed ID: 15265702 [TBL] [Abstract][Full Text] [Related]
48. Proteasome inhibitor Bortezomib induces cell cycle arrest and apoptosis in cell lines derived from Ewing's sarcoma family of tumors and synergizes with TRAIL. Lu G; Punj V; Chaudhary PM Cancer Biol Ther; 2008 Apr; 7(4):603-8. PubMed ID: 18223318 [TBL] [Abstract][Full Text] [Related]
49. Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia. Pahler JC; Ruiz S; Niemer I; Calvert LR; Andreeff M; Keating M; Faderl S; McConkey DJ Clin Cancer Res; 2003 Oct; 9(12):4570-7. PubMed ID: 14555532 [TBL] [Abstract][Full Text] [Related]
50. p53-Independent up-regulation of a TRAIL receptor DR5 by proteasome inhibitors: a mechanism for proteasome inhibitor-enhanced TRAIL-induced apoptosis. Seol DW Biochem Biophys Res Commun; 2011 Dec; 416(1-2):222-5. PubMed ID: 22120628 [TBL] [Abstract][Full Text] [Related]
51. Bortezomib sensitises TRAIL-resistant HPV-positive head and neck cancer cells to TRAIL through a caspase-dependent, E6-independent mechanism. Bullenkamp J; Raulf N; Ayaz B; Walczak H; Kulms D; Odell E; Thavaraj S; Tavassoli M Cell Death Dis; 2014 Oct; 5(10):e1489. PubMed ID: 25341043 [TBL] [Abstract][Full Text] [Related]
52. The flavonolignan silibinin potentiates TRAIL-induced apoptosis in human colon adenocarcinoma and in derived TRAIL-resistant metastatic cells. Kauntz H; Bousserouel S; Gossé F; Raul F Apoptosis; 2012 Aug; 17(8):797-809. PubMed ID: 22555452 [TBL] [Abstract][Full Text] [Related]
53. Increased apoptosis induction in hepatocellular carcinoma by a novel tumor-targeted TRAIL fusion protein combined with bortezomib. Wahl K; Siegemund M; Lehner F; Vondran F; Nüssler A; Länger F; Krech T; Kontermann R; Manns MP; Schulze-Osthoff K; Pfizenmaier K; Bantel H Hepatology; 2013 Feb; 57(2):625-36. PubMed ID: 22991197 [TBL] [Abstract][Full Text] [Related]
54. The proteasome inhibitor bortezomib disrupts tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression and natural killer (NK) cell killing of TRAIL receptor-positive multiple myeloma cells. Feng X; Yan J; Wang Y; Zierath JR; Nordenskjöld M; Henter JI; Fadeel B; Zheng C Mol Immunol; 2010 Aug; 47(14):2388-96. PubMed ID: 20542572 [TBL] [Abstract][Full Text] [Related]
55. Synergistic antiproliferative effect of arsenic trioxide combined with bortezomib in HL60 cell line and primary blasts from patients affected by myeloproliferative disorders. Canestraro M; Galimberti S; Savli H; Palumbo GA; Tibullo D; Nagy B; Guerrini F; Piaggi S; Cine N; Metelli MR; Petrini M Cancer Genet Cytogenet; 2010 Jun; 199(2):110-20. PubMed ID: 20471514 [TBL] [Abstract][Full Text] [Related]
56. Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib. Luster TA; Carrell JA; McCormick K; Sun D; Humphreys R Mol Cancer Ther; 2009 Feb; 8(2):292-302. PubMed ID: 19174554 [TBL] [Abstract][Full Text] [Related]
57. Downregulation of Nrf2 by the combination of TRAIL and Valproic acid induces apoptotic cell death of TRAIL-resistant papillary thyroid cancer cells via suppression of Bcl-xL. Cha HY; Lee BS; Chang JW; Park JK; Han JH; Kim YS; Shin YS; Byeon HK; Kim CH Cancer Lett; 2016 Mar; 372(1):65-74. PubMed ID: 26721202 [TBL] [Abstract][Full Text] [Related]